Profile data is unavailable for this security.
About the company
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
- Revenue in CAD (TTM)0.00
- Net income in CAD-13.98m
- Incorporated2005
- Employees18.00
- LocationResverlogix Corp300-4820 Richard Rd SWCALGARY T3E 6L1CanadaCAN
- Phone+1 (403) 254-9252
- Fax+1 (403) 254-9252
- Websitehttps://www.resverlogix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AEterna Zentaris Inc. | 3.24m | -24.63m | 13.98m | 21.00 | -- | 0.7902 | -- | 4.32 | -20.29 | -20.29 | 2.67 | 14.58 | 0.0572 | 1.52 | 6.36 | -- | -43.46 | -26.24 | -50.57 | -30.34 | 90.69 | 83.68 | -760.32 | -300.31 | 5.93 | -- | 0.0177 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
Avricore Health Inc | 3.49m | -701.22k | 14.99m | -- | -- | 7.44 | -- | 4.30 | -0.007 | -0.007 | 0.035 | 0.0202 | 1.36 | -- | 5.96 | -- | -27.46 | -85.75 | -35.30 | -142.65 | 34.53 | 31.65 | -20.12 | -116.09 | 1.42 | -28.44 | 0.0195 | -- | 97.08 | 196.15 | 14.30 | -- | 80.26 | -- |
Resverlogix Corp | 0.00 | -13.98m | 15.13m | 18.00 | -- | -- | -- | -- | -0.0542 | -0.0542 | 0.00 | -0.3633 | 0.00 | -- | -- | 0.00 | -133.25 | -- | -- | -- | -- | -- | -- | -- | 0.0359 | -1.10 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
Sirona Biochem Corp | 36.35k | -2.65m | 15.40m | -- | -- | -- | -- | 423.71 | -0.0105 | -0.0105 | 0.0001 | -0.011 | 0.0492 | -- | 7.70 | -- | -358.70 | -173.09 | -- | -383.49 | -- | -- | -7,297.85 | -1,405.28 | -- | -9.04 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |
Kane Biotech Inc | 165.60k | -4.94m | 16.50m | -- | -- | -- | -- | 99.62 | -0.0383 | -0.0399 | 0.0013 | -0.089 | 0.0294 | 0.085 | 1.25 | -- | -87.75 | -77.89 | -- | -- | 73.29 | 43.27 | -2,984.41 | -241.85 | 0.2957 | -2.88 | -- | -- | -94.42 | -20.26 | -17.29 | -- | -19.41 | -- |
Hempalta Corp | 0.00 | -3.11k | 16.63m | -- | -- | 1.56 | -- | -- | -0.00007 | -0.00007 | 0.00 | 0.1119 | 0.00 | -- | -- | -- | -0.1168 | -- | -0.1181 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 113.13 | -- | -- | -- |